MST1R and neoplasm: Preclinical data examining RON inhibition show promising results in several cancer types wherein BMS777607-mediated RON inhibition abrogates tumor growth, metastatic progression, and treatment resistance and boosts immune checkpoint inhibitor efficacy [3,26,108,114] in preclinical models.